Literature DB >> 18227732

Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast.

Alaa Afify1, Maaya A McNiel, Jacquelyn Braggin, Helen Bailey, Augusto F Paulino.   

Abstract

BACKGROUND: The interaction between transmembrane receptors on epithelial tumor cells and the surrounding extracellular matrix molecules is important in tumor progression and metastasis. This interaction is best exemplified by the relationship of the receptor CD44 and the extracellular matrix component hyaluronan (HA). This study seeks to evaluate the expression and the correlation of CD44s, CD44v6, and HA in normal, hyperplastic, and malignant breast epithelium and stroma.
MATERIALS AND METHODS: Archival paraffin-embedded tissue from cases of normal breast tissue (n=10), intraductal hyperplasia without atypia (n=13), ductal carcinoma in situ (DCIS) (n=24), stage I infiltrating ductal carcinoma (n=28), stage II infiltrating ductal carcinoma (n=31), and their corresponding positive lymph nodes were retrieved from the surgical pathology files. Tissue sections were evaluated for the expression of CD44s, CD44v6, and HA in the epithelial and stromal cells by immunohistochemistry.
RESULTS: Ductal epithelial cells and myoepithelial cells expressed CD44s in all cases of normal and benign breast tissue. The expression of CD44s in breast epithelium progressively decreased with increasing deviation from normal histology: 83% in DCIS, 46% in stage I ductal carcinoma and 26% in stage II ductal carcinoma. The reverse trend was observed for CD44v6 in ductal epithelium: 0% in normal breast, 15% in intraductal hyperplasia, 100% in DCIS, 82% in stage I infiltrating ductal carcinoma, 94% in stage II carcinoma, and 100% of metastatic carcinoma in the lymph nodes. HA was noted exclusively in the stroma but not in the epithelial cells. HA was faintly expressed in the intralobular stroma of normal breast tissue, confined to a narrow faint band adjacent to intraductal hyperplasia and localized to a broad well-defined band around DCIS. Stromal HA staining was more diffuse and intense in infiltrating carcinomas and was particularly pronounced surrounding the metastatic deposits in lymph nodes.
CONCLUSIONS: This study demonstrates decreased expression of CD44s accompanied by increased expression of CD44v6 and increased stromal HA in breast cancer. These findings suggest that CD44s, CD44v6, and HA play complementary roles in the development and progression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18227732     DOI: 10.1097/PAI.0b013e318047df6d

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  13 in total

1.  Lipid raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration.

Authors:  Simona Donatello; Irina S Babina; Lee D Hazelwood; Arnold D K Hill; Ivan R Nabi; Ann M Hopkins
Journal:  Am J Pathol       Date:  2012-09-29       Impact factor: 4.307

2.  Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.

Authors:  Jae Young So; Hong Jin Lee; Pavel Kramata; Audrey Minden; Nanjoo Suh
Journal:  Mol Cell Pharmacol       Date:  2012-01-01

3.  Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry.

Authors:  Rikke Leth-Larsen; Rikke Lund; Helle V Hansen; Anne-Vibeke Laenkholm; David Tarin; Ole N Jensen; Henrik J Ditzel
Journal:  Mol Cell Proteomics       Date:  2009-03-24       Impact factor: 5.911

4.  Expression of C-KIT, CD24, CD44s, and COX2 in benign and non-invasive apocrine lesions of the breast.

Authors:  Trine Tramm; Jee-Yeon Kim; Sebastian Leibl; Farid Moinfar; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2016-06-10       Impact factor: 4.064

5.  Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study.

Authors:  Jeroen F Vermeulen; Aram S A van Brussel; Arthur Adams; Willem P Th M Mali; Elsken van der Wall; Paul J van Diest; Patrick W B Derksen
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

6.  CD44 is prognostic for overall survival in the NCI randomized trial on breast conservation with 25 year follow-up.

Authors:  T Dan; S M Hewitt; N Ohri; D Ly; B P Soule; S L Smith; K Matsuda; C Council; U Shankavaram; M E Lippman; J B Mitchell; K Camphausen; N L Simone
Journal:  Breast Cancer Res Treat       Date:  2013-11-26       Impact factor: 4.872

7.  Immunophenotyping invasive breast cancer: paving the road for molecular imaging.

Authors:  Jeroen F Vermeulen; Aram S A van Brussel; Petra van der Groep; Folkert H M Morsink; Peter Bult; Elsken van der Wall; Paul J van Diest
Journal:  BMC Cancer       Date:  2012-06-13       Impact factor: 4.430

8.  CD44 increases the efficiency of distant metastasis of breast cancer.

Authors:  Suzanne McFarlane; Jonathan A Coulter; Paul Tibbits; Anthony O'Grady; Cheryl McFarlane; Nicola Montgomery; Ashleigh Hill; Helen O McCarthy; Leonie S Young; Elaine W Kay; Clare M Isacke; David J J Waugh
Journal:  Oncotarget       Date:  2015-05-10

9.  Single-cell heterogeneity in ductal carcinoma in situ of breast.

Authors:  Michael J Gerdes; Yesim Gökmen-Polar; Yunxia Sui; Alberto Santamaria Pang; Nicole LaPlante; Adrian L Harris; Puay-Hoon Tan; Fiona Ginty; Sunil S Badve
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

10.  CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients.

Authors:  Zhonghu Li; Kai Chen; Peng Jiang; Xi Zhang; Xiaowu Li; Zhihua Li
Journal:  Diagn Pathol       Date:  2014-04-08       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.